Afatinib cost effective for EGFRm+ NSCLC in France

Afatinib cost effective for EGFRm+ NSCLC in France PharmacoEconomics & Outcomes News 784, p8 - 12 Aug 2017 Afatinib cost effective for EGFRm+ NSCLC in France First-line treatment with afatinib is cost effective in France for patients with advanced epidermal growth- factor receptor mutation-positive non-small-cell lung cancer (EGFRm+ NSCLC), according to a study published in the Journal of Thoracic Oncology. Tyrokinase inhibitors are approved as first-line therapies for advanced NSCLC with an EGFR gene mutation. The cost effectiveness of two of these agents, afatinib and gefitinib, was compared using a partitioned survival model designed with data from the LUX-Lung 7 trial, the first prospective, multicentre, international, randomised, head-to-head trial of afatinib and gefitinib as first-line treatment for advanced EGFRm+ NSCLC. Direct medial costs were assessed over a 10-year time horizon, with costs estimated using official price lists, published data, fee schedules and questionnaires. A 4% discount rate was applied to costs and benefits. Afatinib was associated with a gain of 0.249 life-years and 0.17 quality-adjusted life-years (QALYs), compared with gefitinib, for the intention-to-treat (ITT) population. Subgroup analyses of patients with EGFR exon-19 deletion (del19) and EGFR exon-21 L858R mutation (L858R) supported this, with gains of 0.257 and 0.247 life-years, respectively, and 0.171 and 0.174 QALYs, respectively, for afatinib versus gefitinib. Afatinib had incremental cost-effectiveness ratios (ICERs) of €45 211, €38 970 and €52 518 for the ITT population, del19 subgroup and L858R subgroup, respectively, compared with gefitinib. Sensitivity analyses demonstrated that afatinib had a 100% probability of being cost effective for patients with common EGFR mutations at a willingness-to-pay (WTP) threshold of €70 000 per QALY. The authors noted that although cost-effectiveness analyses are mandatory in France for innovative drugs, there is no official WTP threshold. They concluded that "the World Health Organization-recommended conventional benchmark is an acceptable ICER-value range of 1–3 gross national product per capita, which would mean 2015 values of €32,735–€98,205 in France. The ICERs for all tested scenarios fell in that range". Chouaid C, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology : 24 Jul 2017 803262860 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Afatinib cost effective for EGFRm+ NSCLC in France

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/afatinib-cost-effective-for-egfrm-nsclc-in-france-ZqIP2ESbRD
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4219-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p8 - 12 Aug 2017 Afatinib cost effective for EGFRm+ NSCLC in France First-line treatment with afatinib is cost effective in France for patients with advanced epidermal growth- factor receptor mutation-positive non-small-cell lung cancer (EGFRm+ NSCLC), according to a study published in the Journal of Thoracic Oncology. Tyrokinase inhibitors are approved as first-line therapies for advanced NSCLC with an EGFR gene mutation. The cost effectiveness of two of these agents, afatinib and gefitinib, was compared using a partitioned survival model designed with data from the LUX-Lung 7 trial, the first prospective, multicentre, international, randomised, head-to-head trial of afatinib and gefitinib as first-line treatment for advanced EGFRm+ NSCLC. Direct medial costs were assessed over a 10-year time horizon, with costs estimated using official price lists, published data, fee schedules and questionnaires. A 4% discount rate was applied to costs and benefits. Afatinib was associated with a gain of 0.249 life-years and 0.17 quality-adjusted life-years (QALYs), compared with gefitinib, for the intention-to-treat (ITT) population. Subgroup analyses of patients with EGFR exon-19 deletion (del19) and EGFR exon-21 L858R mutation (L858R) supported this, with gains of 0.257 and 0.247 life-years, respectively, and 0.171 and 0.174 QALYs, respectively, for afatinib versus gefitinib. Afatinib had incremental cost-effectiveness ratios (ICERs) of €45 211, €38 970 and €52 518 for the ITT population, del19 subgroup and L858R subgroup, respectively, compared with gefitinib. Sensitivity analyses demonstrated that afatinib had a 100% probability of being cost effective for patients with common EGFR mutations at a willingness-to-pay (WTP) threshold of €70 000 per QALY. The authors noted that although cost-effectiveness analyses are mandatory in France for innovative drugs, there is no official WTP threshold. They concluded that "the World Health Organization-recommended conventional benchmark is an acceptable ICER-value range of 1–3 gross national product per capita, which would mean 2015 values of €32,735–€98,205 in France. The ICERs for all tested scenarios fell in that range". Chouaid C, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology : 24 Jul 2017 803262860 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off